MRNA Oct 2024 130.000 call
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
As of 02:48PM EDT. Market open.
Loading interactive chart...
- Zacks
The Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers
Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers are included in this Analyst Blog.
- Zacks
Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
Novavax, Inc (NVAX) and Fulcrum Therapeutics, Inc (FULC) are in the spotlight following license agreements with pharma giant Sanofi.
- Investor's Business Daily
Moderna Stock Rebounds From Its RSV Vaccine Fallout — Is It A Buy, Again?
Moderna is on the rise after the Food and Drug Administration delayed a decision on its RSV vaccine. But is MRNA stock, once again, a buy?
© 2024 Yahoo. All rights reserved.